Kyle Doherty

2 days ago | onclive.com | Kyle Doherty

The presence of large clones of clonal hematopoiesis was associated with worse progression-free survival (PFS) and overall survival (OS) in patients with treatment-naive mantle cell lymphoma (MCL) who received maintenance therapy with lenalidomide (Revlimid) or observation following chemoimmunotherapy and autologous stem cell transplantation (ASCT), according to data from an analysis of the phase 3 MCL0208 trial (NCT02354313) published in Blood Advances.1 At a median follow-up of 7 years,...

3 days ago | onclive.com | Kyle Doherty

Treatment with belzutifan (Welireg) led to high response rates in patients with von Hippel-Lindau (VHL)–associated renal cell carcinoma (RCC) and other neoplasms, according to data from the phase 2 LITESPARK-004 trial (NCT03401788) published in Lancet Oncology.

4 days ago | onclive.com | Kyle Doherty

Patients with chronic lymphocytic leukemia (CLL) who experienced disease progression following treatment with zanubrutinib (Brukinsa) or ibrutinib (Imbruvica) had a low rate of BTK-mutated disease, according to findings from an analysis of the phase 3 ALPINE trial (NCT03734016) published in Blood Advances.1 At a median follow-up of 25.7 months for the final progression-free survival (PFS) analysis, data demonstrated that BTK mutations occurred in 5 and 3 evaluable patients with...

6 days ago | onclive.com | Kyle Doherty

The Inflation Reduction Act (IRA), which was signed into law in 2022, contains provisions designed to lower drug prices for Medicare beneficiaries.1 Although significant savings have already been reported,2 the legislation may have unintended consequences on oncologic drug development, access, and innovation, according to Frank S. David, MD, PhD.3“There are 3 main provisions of the IRA that affect pharmaceuticals,” David wrote in a statement to OncologyLive.

1 week ago | onclive.com | Kyle Doherty

With the development of novel RAS(ON) inhibitors such as zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), investigators are aiming to surmount acquired resistance in patients with pretreated solid tumors following treatment with currently available RAS inhibitors.